A Clinical Trial of the Low Dose Chidamide in the Management of Refractory ITP
Status:
Unknown status
Trial end date:
2020-09-01
Target enrollment:
Participant gender:
Summary
Nowdays HDACi's were more and more focused on the anti-inflammatory and immunomodulatory
activities,independent of their known proapoptotic or cell cycle arrest actions on malignant
cells. Low concentrations of HDACi's are effective in reducing inflammation and autoimmune
response in humans with juvenile idiopathic arthritis and animal models of inflammatory bowel
disease and arthritis. The project was undertaking by Qilu Hospital of Shandong University in
China. In order to report the efficacy and safety of the low dose chidamide in the management
of refractory ITP.